Rajat Sandhir
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Rajat Sandhir has a total of 145 co-authors. Here are the top co-authors by number of shared publications:
Arpit Mehrotra
Department of Biochemistry, Hargobind Khorana Block, Panjab University, Sector-25, Chandigarh, 160014, India
12 shared publicationsAditya Sunkaria
Department of Biochemistry, Basic Medical Sciences Block-II, Sector-25, Panjab University, Chandigarh 160014, India
8 shared publications- Mohit Kumar
BRIC-National Agri-Food & Biomanufacturing Institute (NABI), (formerly National Agri-Food Biotechnology Institute), Knowledge City-Sector 81, SAS Nagar, Punjab-140306, India
8 shared publications Aarti Yadav
Department of Biochemistry, Basic Medical Science Block-II, Panjab University, Chandigarh, 160014, India
6 shared publicationsRavi Kiran
Panjab University
6 shared publications- Aanchal Aggarwal
National Agri-Food Biomanufacturing Institute, Knowledge City, Sector-81, SAS Nagar, Punjab 140306, India
5 shared publications
Latest Publications
- 22 October 2026
- Published by Elsevier in Ageing Research Reviews
- Vol. 123, 103426
Receptor-specific ER-phagy in neurodegenerative diseases: Molecular mechanisms and emerging therapeutic opportunities
- 22 October 2026
- Published by Elsevier in Ageing Research Reviews
- Vol. 123, 103426
Receptor-specific ER-phagy in neurodegenerative diseases: Molecular mechanisms and emerging therapeutic opportunities
- 29 May 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1)
Differential expression of PPAR isoforms in streptozotocin induced model of sporadic alzheimer’s disease in zebrafish
Sporadic Alzheimer's Disease (sAD) is a multifactorial neurodegenerative disorder in which metabolic dysfunctions and central insulin resistance are recognized as key pathogenic drivers accompanied by amyloid and tau pathology. Effective disease-modifying therapies remain elusive, representing a major global public health concern. Peroxisome proliferator-activated receptors (PPARs) have emerged as promising therapeutic targets due to their roles in regulating neuroinflammation, lipid metabolism and insulin sensitivity. Despite extensive studies highlighting the distinct role of PPAR isoforms in neurodegeneration, their involvement in sAD pathology remains unexplored. The role of PPARs was evaluated in streptozotocin (STZ) model of sAD. STZ was administered intracerebroventricularly at a dose of 5 mg/kg for 7 days. The cognitive functions and expression of PPAR isoforms and its downstream targets were investigated in adult zebrafish. STZ-treated zebrafish exhibited significant cognitive impairment with decreased preference for the novel object indicating working memory deficits. Molecular analysis revealed isoform-specific modulation of PPARs. PPARα was upregulated, whereas its downstream targets (acox1, cpt1, map3k8) were downregulated suggesting impaired transcriptional activation. PPARγ, PPARβ/δ and their targets were significantly downregulated at both transcript and protein levels suggesting suppression of their neuroprotective functions. Immunofluorescence revealed distinct spatial localization patterns; PPARα was prominent in telencephalon and optic tectum; PPARγ showed punctate nuclear expression in preoptic area; and PPARβ/δ displayed diffuse nuclear staining in diencephalon. These findings demonstrate that STZ-induced cognitive deficits are accompanied by region-specific dysregulation in expression of PPAR isoforms suggesting that PPAR modulation may be a therapeutic strategy to prevent sAD pathogenesis.
- 29 May 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1)
Differential expression of PPAR isoforms in streptozotocin induced model of sporadic alzheimer’s disease in zebrafish
Sporadic Alzheimer's Disease (sAD) is a multifactorial neurodegenerative disorder in which metabolic dysfunctions and central insulin resistance are recognized as key pathogenic drivers accompanied by amyloid and tau pathology. Effective disease-modifying therapies remain elusive, representing a major global public health concern. Peroxisome proliferator-activated receptors (PPARs) have emerged as promising therapeutic targets due to their roles in regulating neuroinflammation, lipid metabolism and insulin sensitivity. Despite extensive studies highlighting the distinct role of PPAR isoforms in neurodegeneration, their involvement in sAD pathology remains unexplored. The role of PPARs was evaluated in streptozotocin (STZ) model of sAD. STZ was administered intracerebroventricularly at a dose of 5 mg/kg for 7 days. The cognitive functions and expression of PPAR isoforms and its downstream targets were investigated in adult zebrafish. STZ-treated zebrafish exhibited significant cognitive impairment with decreased preference for the novel object indicating working memory deficits. Molecular analysis revealed isoform-specific modulation of PPARs. PPARα was upregulated, whereas its downstream targets (acox1, cpt1, map3k8) were downregulated suggesting impaired transcriptional activation. PPARγ, PPARβ/δ and their targets were significantly downregulated at both transcript and protein levels suggesting suppression of their neuroprotective functions. Immunofluorescence revealed distinct spatial localization patterns; PPARα was prominent in telencephalon and optic tectum; PPARγ showed punctate nuclear expression in preoptic area; and PPARβ/δ displayed diffuse nuclear staining in diencephalon. These findings demonstrate that STZ-induced cognitive deficits are accompanied by region-specific dysregulation in expression of PPAR isoforms suggesting that PPAR modulation may be a therapeutic strategy to prevent sAD pathogenesis.
- 1 April 2025
- Published by Wiley in Journal of Neuroscience Research
- Vol. 103 (4) , e70032
An Interplay Between Hypothalamic Microstructure, Systemic Metabolism and Gut Microbiome Composition in Male Rats at Hyperacute Timepoint Post TBI
Traumatic brain injury (TBI) is an insult to the brain that impacts neuronal and non‐neuronal cells/tissues. The study aimed to understand TBI‐induced early changes in the brain and systemic physiology. The male rats were subjected to mild and moderate TBI, where serum and urine metabolic fingerprints of mild TBI rats showed a hypermetabolic response with increased energy metabolites, amino acids, and gut metabolites in serum and increased TCA cycle intermediates in urine. In contrast, the moderate TBI rats showed decreased lactate, pyruvate, amino acids (glycine and leucine) and gut metabolites [trimethylamine N OXIDE (TMAO), choline and acetate] in serum. The urine showed increased pyruvate, creatinine, and allantoin levels. To understand the brain's role in altered metabolic physiology, hypothalamus structure was assessed using diffusion tensor imaging (DTI) and stress levels were observed using serum corticosterone. The injured rats exhibited changes in DTI metrics in the hypothalamus, suggesting a potential disruption in the regulation of the hypothalamus‐pituitary–adrenal axis (HPA) axis. These alterations were accompanied by increased TNF‐α levels after moderate TBI. The injury induced allostatic overload, accompanied by impaired hypothalamic structure, and metabolic physiology also showed gut microbiome dysbiosis. The gut microbiome showed an increased Firmicutes: Bacteroidetes ratio after injury, with variable gut composition after both injuries. Therefore, the present study provides insight into an interplay between the HPA axis, metabolism, and gut microbiome following TBI. Importantly, this crosstalk between the regulatory systems was different after mild and moderate injury, highlighting the need to assess injury phenotype based on the severity.
- 1 April 2025
- Published by Wiley in Journal of Neuroscience Research
- Vol. 103 (4) , e70032
An Interplay Between Hypothalamic Microstructure, Systemic Metabolism and Gut Microbiome Composition in Male Rats at Hyperacute Timepoint Post TBI
Traumatic brain injury (TBI) is an insult to the brain that impacts neuronal and non‐neuronal cells/tissues. The study aimed to understand TBI‐induced early changes in the brain and systemic physiology. The male rats were subjected to mild and moderate TBI, where serum and urine metabolic fingerprints of mild TBI rats showed a hypermetabolic response with increased energy metabolites, amino acids, and gut metabolites in serum and increased TCA cycle intermediates in urine. In contrast, the moderate TBI rats showed decreased lactate, pyruvate, amino acids (glycine and leucine) and gut metabolites [trimethylamine N OXIDE (TMAO), choline and acetate] in serum. The urine showed increased pyruvate, creatinine, and allantoin levels. To understand the brain's role in altered metabolic physiology, hypothalamus structure was assessed using diffusion tensor imaging (DTI) and stress levels were observed using serum corticosterone. The injured rats exhibited changes in DTI metrics in the hypothalamus, suggesting a potential disruption in the regulation of the hypothalamus‐pituitary–adrenal axis (HPA) axis. These alterations were accompanied by increased TNF‐α levels after moderate TBI. The injury induced allostatic overload, accompanied by impaired hypothalamic structure, and metabolic physiology also showed gut microbiome dysbiosis. The gut microbiome showed an increased Firmicutes: Bacteroidetes ratio after injury, with variable gut composition after both injuries. Therefore, the present study provides insight into an interplay between the HPA axis, metabolism, and gut microbiome following TBI. Importantly, this crosstalk between the regulatory systems was different after mild and moderate injury, highlighting the need to assess injury phenotype based on the severity.
- Open Access
- 21 February 2025
- Published by Elsevier in IBRO Neuroscience Reports
- Vol. 18, 512-519
N-acetyl-L-cysteine mitigates diabetes-induced impairments in sciatic nerve
- 21 February 2025
- Published by Elsevier in IBRO Neuroscience Reports
- Vol. 18, 512-519
Open AccessN-acetyl-L-cysteine mitigates diabetes-induced impairments in sciatic nerve
- 4 December 2024
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 15 (24) , 4478-4499
1H NMR-Based Metabolomic Signatures in Rodent Models of Sporadic Alzheimer’s Disease and Metabolic Disorders
Alzheimer's disease (AD) is a chronic neurological disorder that impacts the elderly population all over the globe. Evidence suggests association between AD and metabolic disorders such as diabetes mellitus (DM) and obesity (OB). The present study is an attempt to evaluate metabolic alterations in the serum and brain through NMR spectroscopy with the aim to identify shared metabolic signatures. AD was induced in rats by stereotactic intracerebroventricular injection of oligomerized A beta-42 peptide into the brain. DM and OB were induced by intraperitoneal injection of streptozotocin and feeding rats on a high-fat diet, respectively. The metabolic alterations obtained through 1H NMR spectroscopy were further subjected to multivariate analysis by principal component analysis and partial least-squares discrimination for identification of metabolic signatures. In the serum, the levels of lactate and betaine were increased in AD, DM, and OB rats. On the other hand, the metabolite profile of brain indicated increase in the levels of lactate, N-acetylaspartate, and creatinine in AD, DM, and OB rats. Additionally, the concentration of neurochemicals such as glutamate, GABA, N-acetylglutamate, and myo-inositol were also elevated. The alterations in neurotransmitters and cerebral energy metabolism were accompanied by deficits in cognition assessed by Morris water maze in AD, DM, and OB rats. The perturbed metabolic profiles were accompanied by the presence of pathogenic amyloid deposits visualized by Congo red stain in the brains of AD, DM, and OB rats. Overall, the study identifies common metabolic signatures in AD, DM, and OB that may be involved in etiopathogenesis and also suggests linkages between these three conditions.
- 4 December 2024
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 15 (24) , 4478-4499
1H NMR-Based Metabolomic Signatures in Rodent Models of Sporadic Alzheimer’s Disease and Metabolic Disorders
Alzheimer's disease (AD) is a chronic neurological disorder that impacts the elderly population all over the globe. Evidence suggests association between AD and metabolic disorders such as diabetes mellitus (DM) and obesity (OB). The present study is an attempt to evaluate metabolic alterations in the serum and brain through NMR spectroscopy with the aim to identify shared metabolic signatures. AD was induced in rats by stereotactic intracerebroventricular injection of oligomerized A beta-42 peptide into the brain. DM and OB were induced by intraperitoneal injection of streptozotocin and feeding rats on a high-fat diet, respectively. The metabolic alterations obtained through 1H NMR spectroscopy were further subjected to multivariate analysis by principal component analysis and partial least-squares discrimination for identification of metabolic signatures. In the serum, the levels of lactate and betaine were increased in AD, DM, and OB rats. On the other hand, the metabolite profile of brain indicated increase in the levels of lactate, N-acetylaspartate, and creatinine in AD, DM, and OB rats. Additionally, the concentration of neurochemicals such as glutamate, GABA, N-acetylglutamate, and myo-inositol were also elevated. The alterations in neurotransmitters and cerebral energy metabolism were accompanied by deficits in cognition assessed by Morris water maze in AD, DM, and OB rats. The perturbed metabolic profiles were accompanied by the presence of pathogenic amyloid deposits visualized by Congo red stain in the brains of AD, DM, and OB rats. Overall, the study identifies common metabolic signatures in AD, DM, and OB that may be involved in etiopathogenesis and also suggests linkages between these three conditions.
- 28 October 2024
- Published by Elsevier in Experimental Neurology
- Vol. 383, 115034
Zebrafish as a model organism to study sporadic Alzheimer's disease: Behavioural, biochemical and histological validation
- 28 October 2024
- Published by Elsevier in Experimental Neurology
- Vol. 383, 115034
Zebrafish as a model organism to study sporadic Alzheimer's disease: Behavioural, biochemical and histological validation
- 28 September 2024
- Published by Elsevier in Neurochemistry International
- Vol. 180, 105867
Neuroprotective effects of Withania somnifera on ischemic stroke are mediated via anti-inflammatory response and modulation of neurotransmitter levels
- 28 September 2024
- Published by Elsevier in Neurochemistry International
- Vol. 180, 105867
Neuroprotective effects of Withania somnifera on ischemic stroke are mediated via anti-inflammatory response and modulation of neurotransmitter levels
- Open Access
- 1 June 2023
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 38 (6) , 2185-2186
Correction to: Indian ginseng (Withania somnifera) supplementation ameliorates oxidative stress and mitochondrial dysfunctions in experimental model of stroke
- 1 June 2023
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 38 (6) , 2185-2186
Open AccessCorrection to: Indian ginseng (Withania somnifera) supplementation ameliorates oxidative stress and mitochondrial dysfunctions in experimental model of stroke
- 16 November 2022
- Published by Springer Nature in Journal of Proteins and Proteomics
- Vol. 13 (4) , 227-245
Identification of potential inhibitors of brain-specific CYP46A1 from phytoconstituents in Indian traditional medicinal plants
Cytochrome P450 46A1 (CYP46A1) is a crucial enzyme in brain that converts cholesterol to 24 (S) hydroxy cholesterol thereby increasing its polarity to facilitate removal of excess cholesterol from the CNS. The inhibition of CYP46A1 with several synthetic molecules has been investigated extensively for treatment of Alzheimer’s disease, Huntington’s disease, glaucoma, and in hippocampal neurons from aged mice. However, phytochemicals have received far little attention in studies involving development of potential CYP46A1 inhibitors. Thus, in the present study phytoconstituents from Indian traditional medicinal plants; Bacopa monnieri, Piper longum, and Withania somnifera, were virtually screened for interaction with CYP46A1 using computational tools. Out of three plants, six molecules from P. longum and three molecules from W. somnifera were shortlisted to study interactions with CYP46A1 based on the physio-chemical parameters. Fargesin, piperolactam A and coumaperine from P. longum showed the higher binding affinity and the values were − 10.3, − 9.5, − 9.0 kcal/moles respectively, whereas, withaferin A from W. somnifera had a binding affinity of − 12.9 kcal/mol. These were selected as potential modulators as they exhibited suitable interactions with active site residues; Tyr109, Leu112, Trp368, Gly369, and Ala474. The selected molecules were further subjected to molecular dynamics simulation. Further, the pharmacological properties of molecules were also predicted using ADMET calculator and the data revealed that all the selected compounds had good absorption as well as solubility characteristics. In addition, sesamin, fargesin, piperolactam A, and coumaperine had minimal or no toxic effects. Thus, the study successfully identified compounds from Indian medicinal plants that may serve as potential inhibitors of CYP46A1 or base structures to design novel CYP46A1 inhibitors, which may be effective in treating neurological conditions involving perturbed cholesterol homeostasis.
- 16 November 2022
- Published by Springer Nature in Journal of Proteins and Proteomics
- Vol. 13 (4) , 227-245
Identification of potential inhibitors of brain-specific CYP46A1 from phytoconstituents in Indian traditional medicinal plants
Cytochrome P450 46A1 (CYP46A1) is a crucial enzyme in brain that converts cholesterol to 24 (S) hydroxy cholesterol thereby increasing its polarity to facilitate removal of excess cholesterol from the CNS. The inhibition of CYP46A1 with several synthetic molecules has been investigated extensively for treatment of Alzheimer’s disease, Huntington’s disease, glaucoma, and in hippocampal neurons from aged mice. However, phytochemicals have received far little attention in studies involving development of potential CYP46A1 inhibitors. Thus, in the present study phytoconstituents from Indian traditional medicinal plants; Bacopa monnieri, Piper longum, and Withania somnifera, were virtually screened for interaction with CYP46A1 using computational tools. Out of three plants, six molecules from P. longum and three molecules from W. somnifera were shortlisted to study interactions with CYP46A1 based on the physio-chemical parameters. Fargesin, piperolactam A and coumaperine from P. longum showed the higher binding affinity and the values were − 10.3, − 9.5, − 9.0 kcal/moles respectively, whereas, withaferin A from W. somnifera had a binding affinity of − 12.9 kcal/mol. These were selected as potential modulators as they exhibited suitable interactions with active site residues; Tyr109, Leu112, Trp368, Gly369, and Ala474. The selected molecules were further subjected to molecular dynamics simulation. Further, the pharmacological properties of molecules were also predicted using ADMET calculator and the data revealed that all the selected compounds had good absorption as well as solubility characteristics. In addition, sesamin, fargesin, piperolactam A, and coumaperine had minimal or no toxic effects. Thus, the study successfully identified compounds from Indian medicinal plants that may serve as potential inhibitors of CYP46A1 or base structures to design novel CYP46A1 inhibitors, which may be effective in treating neurological conditions involving perturbed cholesterol homeostasis.